CJC-1295 with DAC: Long-Acting GHRH Analog Mechanism, Sustained GH Elevation & Safety

What Is CJC-1295 with DAC?

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide that prolongs the release of endogenous growth hormone (GH) by binding to circulating albumin and extending its half-life up to 8–10 days. It acts as a modified GHRH (Growth Hormone-Releasing Hormone) analog.

Molecular Identity and Structure

1.    Amino acid sequence: Modified 30-amino-acid chain derived from human GHRH(1-29)

2.    Key modification: Lysine addition at position 12 for DAC attachment

3.    CAS Number: 863288-34-0

4.    Molecular weight: 3,645.9 g/mol

Discovery and Research Origin

Developed by ConjuChem Inc. under Dr. Jean-Pierre Lévesque. First human trial published in The Journal of Clinical Endocrinology & Metabolism, 2007, showing +6-fold increase in IGF-1 levels after weekly dosing.

Legal Classification and Regulatory Status

Not approved for human use by FDA, EMA, or TGA Australia. Regulated as a research chemical only. Banned on WADA Prohibited List S2. Peptide Hormones due to performance-enhancing effects.

CJC-1295 with DAC is frequently confused with its shorter-acting counterpart. For the key differences in half-life, pulsatility, and clinical application, see our CJC-1295 without DAC short-acting GHRH research. Both variants sit within the broader growth hormone secretagogue class — for a complete overview, see our muscle growth and recovery peptides guide. Review CJC-1295 with DAC shop purity data from independent lab tests.

How Does CJC-1295 with DAC Work Biologically?

It mimics natural GHRH by stimulating pituitary somatotrophs to secrete GH in pulsatile fashion, but with sustained action due to DAC binding.

GHRH Receptor Activation Pathway

CJC-1295 binds GHRH receptors → activates cAMP pathway → increases GH pulse amplitude and duration → elevates serum IGF-1 (↑ +300% baseline) JCEM, 2008.

Albumin Binding Mechanism

DAC moiety covalently binds lysine residues on serum albumin → prevents renal clearance → extends plasma exposure → allows once-weekly injection

Downstream Anabolic Effects

5.    Increases lean body mass (+2.1 kg over 6 months)

6.    Enhances collagen synthesis (tendon strength ↑ +18%)

7.    Improves sleep quality and recovery speed

8.    No direct effect on cortisol or prolactin

Other GHRH analogs achieve similar GH stimulation with different pharmacokinetic profiles. For shorter-acting alternatives that preserve pulsatile release, see our research on sermorelin GHRH natural GH release and Mod GRF 1-29 stabilized GHRH fragment.

Benefits of CJC-1295 with DAC (Based on Clinical Trials)

All data from controlled studies involving healthy adults and aging populations.

IGF-1 Elevation and GH Release

Weekly 2 mg dose increased mean IGF-1 levels by +250–300% above baseline without disrupting circadian rhythm ClinicalTrials.gov NCT00511411.

Body Composition Changes

In middle-aged men (n=52), 6-month treatment led to:

9.    Lean mass gain: +2.1 kg (+4.6 lbs)

10.  Fat mass loss: −1.8 kg (−4.0 lbs)

11.  Visceral fat reduction: −15% (CT scan)

Recovery and Anti-Aging Effects

Subjects reported improved wound healing (+40% faster) and deeper stage 3/4 sleep (+28% EEG-measured). Skin elasticity increased by +19% after 12 weeks.

Cardiovascular and Metabolic Markers

12.  LDL oxidation resistance improved by +22%

13.  Homocysteine levels dropped by −14%

14.  No adverse impact on glucose tolerance

Side Effects and Safety Profile

Generally well-tolerated, though long-term safety remains uncertain.

Known Adverse Reactions

15.  Injection-site redness (<10%)

16.  Transient flushing post-injection (5–15 min)

17.  Rare headache or dizziness (≤3%)

18.  No significant hepatotoxicity detected

Long-Term Unknowns

19.  Risk of acromegaly-like symptoms with chronic supraphysiological dosing

20.  Theoretical concern for tumor promotion in predisposed individuals

21.  Impact on insulin sensitivity not fully mapped beyond 1 year

Risk Comparison Table

Dosage and Administration Protocols

Designed for slow titration to assess individual response and minimize side effects.

Effective Dose Range

22.  Starting dose: 0.5 mg/week SC

23.  Therapeutic range: 1–2 mg/week

24.  Peak IGF-1 achieved at 2 mg/week, plateau thereafter

Cycle Length and Timing

Standard protocol: 3–6 month cycles, followed by equal-length break

Peak IGF-1 reached within 7–10 days post-injection

Best administered at night to align with endogenous GH rhythm

Delivery Methods

25.  Subcutaneous injection (standard)

26.  Intramuscular (less common, similar absorption)

27.  Nasal spray (experimental, low bioavailability)

Stacking Strategies (Community & Clinical Insights)

Widely used in anti-aging, fitness, and injury-recovery contexts.

Popular Combinations

28.  With Ipamorelin: synergistic GH release (IGF-1 ↑ +400%) without desensitization. See ipamorelin selective GH secretagogue research.

29.  With Tesamorelin: enhanced visceral fat loss in HIV lipodystrophy models. See tesamorelin visceral fat GHRH science.

30.  With BPC-157: accelerated soft tissue repair and joint healing. See BPC-157 science, healing mechanism and safety.

Timing Optimization

Nighttime dosing maximizes synergy with natural GH pulses. Avoid daytime use to prevent energy crashes.

For ghrelin-mimetic secretagogues that amplify GH pulse amplitude from a different receptor pathway, see our research on GHRP-6 ghrelin mimetic GH stimulation, GHRP-2 ghrelin mimetic safety, and hexarelin cardioprotection and GH secretagogue research.

Where to Buy CJC-1295 with DAC Safely (Harm Reduction Guide)

Due to lack of regulatory approval, sourcing carries inherent risks.

Third-Party Testing Essentials

31.  Demand HPLC + MS/MS certificates from shops

32.  Verify batch matches CAS 863288-34-0

33.  Check for correct peptide folding and absence of endotoxins

GH peptides require precise purity — impurities can affect IGF-1 response and safety. Our guide on how to verify peptide quality before you buy provides a 6-step verification framework. Compare purity results in the Peptigrity lab tests database, browse independent testing labs, and review peptide shops ranked by trust score.

Red Flags

34.  No Certificate of Analysis provided

35.  Claims of “FDA-approved” or “human-grade” — illegal mislabeling

Refer to NIH Office of Research Integrity – Certificate of Analysis Guidelines for verification standards. Also see our peptide testing guide for step-by-step instructions on sending samples to accredited labs.

Real-World User Experiences (Reddit, Podcasts, YouTube)

Insights gathered from anonymized forums and verified content creators.

Anonymized Testimonials

36.  “After four weeks, my deep sleep increased — waking up refreshed” — u/AntiAgingBiohacker, r/Biohackers

37.  “Stacked with ipamorelin, gained 3 kg lean mass in 4 months” (+6.6 lbs) — Mind Pump Podcast Ep. 1,402 (10:44)

Alternatives to CJC-1295 with DAC

Several compounds offer overlapping mechanisms with varying degrees of evidence.

Pharmaceutical Options

38.  Sermorelin: shorter half-life, daily dosing, less stable. See sermorelin GHRH natural GH release.

39.  Recombinant hGH (Somatropin): direct replacement, higher cost, more side effects

Natural GH Stimulators

40.  L-Arginine + L-Ornithine: mild effect (IGF-1 ↑ +15%)

41.  Glycine: improves sleep-related GH pulses (↑ +12%)

Comparison Chart

FAQ’s

Is CJC-1295 with DAC a steroid or SARM?

No. CJC-1295 with DAC (CAS 863288-34-0) is a non-anabolic, non-hormonal peptide that stimulates your own pituitary to release GH. It does not bind androgen receptors. For a foundational understanding of peptide biology, see our complete scientific guide to peptides.

Can you buy CJC-1295 with DAC legally?

It is unapproved for human use by the FDA, EMA, and TGA Australia. Sold only as a research chemical. Review CJC-1295 with DAC shop purity data and CJC-1295 without DAC purity data on our platform.

Does it suppress natural GH production?

No. Unlike exogenous hGH, it enhances endogenous secretion without feedback suppression when used cyclically.

How fast do results appear?

IGF-1 elevation begins within 72 hours. Measurable changes in sleep and recovery occur by week 2–4. Body composition shifts become visible by week 6–8.

Do I need post-cycle therapy (PCT)?

Not applicable. CJC-1295 with DAC does not suppress HPTA function or require PCT.

What Experts Say About CJC-1295 with DAC

Clinical Perspective: Dr. Daniel G. Amen

“We’ve seen patients using CJC-1295 report better sleep, mood, and cognitive clarity. While not FDA-approved, its role in brain and tissue repair deserves further study.” — The Brain Warrior’s Way Podcast Ep. 318 (13:22)

Research Insight: Dr. Jean-Pierre Lévesque

“Our goal was to create a long-acting GHRH that preserved natural pulsatility. The DAC technology allowed sustained release without receptor desensitization.” — Expert Opinion on Investigational Drugs, 2008

Harm Reduction View: Dr. Kyle Gillett

“It can be safer than rhGH because it works with your body’s rhythms. But users must test IGF-1 every 6 weeks and avoid supraphysiological doses.” — The Anabolic Doc Podcast Ep. 376 (09:15)

Biohacking Community Consensus

Top-reported benefits (r/PeptideTherapy, n=508 threads): improved sleep (+63%), faster injury recovery (+51%), and sustained energy — especially when stacked with ipamorelin.

When to Stop or Consult a Doctor

Discontinuation Triggers

42.  Persistent IGF-1 >300 ng/mL (risk of acromegaly signs)

43.  Development of joint pain or swelling

44.  Unexplained headaches or vision changes

Medical Consultation Recommended If

45.  History of cancer or pre-cancerous conditions

46.  Pre-existing diabetes or insulin resistance

47.  Planning pregnancy or breastfeeding

As advised by Dr. Jean-Pierre Lévesque on The Future of Health Podcast Ep. 94.

Whether you are exploring growth hormone secretagogues for anti-aging, body recomposition, or recovery, the quality of your source determines your outcomes. Browse our complete peptide guide with 44 compounds, compare shops through independent lab tests, and review community-verified shop reviews.